Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.
暂无分享,去创建一个
Derek Y. Chiang | A. Zhu | J. Furuse | Yoon-Koo Kang | B. Daniele | R. Poon | Li‐Tzong Chen | A. Vogel | M. Voi | Wei He | David J. Chen | M. Kanai
[1] E. Erdal,et al. Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells , 2016, Cancer science.
[2] C. Porta,et al. Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). , 2016 .
[3] Lin Qiu,et al. Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade , 2015, Hepatology.
[4] J. Zucman‐Rossi,et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.
[5] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[6] H. Huynh,et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus , 2015, Molecular Cancer Therapeutics.
[7] L. Roberts,et al. Update on biomarkers of hepatocellular carcinoma. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[9] D. Spaeth,et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. , 2015, Annals of Oncology.
[10] J. Llovet,et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era , 2015, Nature Reviews Clinical Oncology.
[11] N. Shikata,et al. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma , 2015, Digestive Diseases and Sciences.
[12] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[13] W. Sung,et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.
[14] Nikhil Wagle,et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.
[15] M. Kudo,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.
[16] Yitao Ding,et al. Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways , 2014, BioMed research international.
[17] S. Imbeaud,et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas , 2014, Gut.
[18] P. Schirmacher,et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. , 2014, Cancer discovery.
[19] L. Schwartz,et al. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. , 2014, Hepatic oncology.
[20] C. Sander,et al. Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.
[21] J. Llovet,et al. Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.
[22] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[23] Su Jin Lee,et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. , 2013, Anticancer research.
[24] F. Eren,et al. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. , 2013, Annals of hepatology.
[25] J. Zucman‐Rossi,et al. Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.
[26] Lin Li,et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma , 2013, Genome research.
[27] P. Zhan,et al. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. , 2013, Hepatobiliary surgery and nutrition.
[28] Y. Kodera,et al. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. , 2013, Cancer letters.
[29] Derek Y. Chiang,et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing , 2013, Hepatology.
[30] Tohru Utsunomiya,et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma , 2013, Hepatology.
[31] A. Zhu,et al. Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.
[32] D. Sahani,et al. Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study , 2013, Clinical Cancer Research.
[33] A. Gasbarrini,et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.
[34] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[35] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.
[36] S. Imbeaud,et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.
[37] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[38] M. Ryu,et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum , 2012, British Journal of Cancer.
[39] D. Fingar,et al. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. , 2012, The Biochemical journal.
[40] H. Ueno,et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma , 2013, International Journal of Clinical Oncology.
[41] Jeffrey S. Morris,et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. Weigelt,et al. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.
[43] Takafumi Yoshida,et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. , 2010, Oncology reports.
[44] Derek Y. Chiang,et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. , 2010, Journal of hepatology.
[45] Derek Y. Chiang,et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.
[46] G. Gores,et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.
[47] H. Lane,et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition , 2009, Molecular Cancer Therapeutics.
[48] Jaume Bosch,et al. Angiogenesis in liver disease. , 2009, Journal of hepatology.
[49] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[50] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[51] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[52] S. Boyault,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.
[53] S. Thorgeirsson,et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.
[54] M. Torbenson,et al. mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.
[55] G. Thomas,et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.